CClinicalTrials.gg
CompletedNCT04365686Updated Apr 28, 2020

Smooth Extubation With Ketofol for Induction of General Anesthesia in Laparoscopic Drilling of Polycystic Ovary

A Phase 4 interventional study of Ketofol as induction agent and Propofol as induction agent in Smooth Extubation, sponsored by Fayoum University Hospital. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Fayoum University Hospital · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Apr 2019, registered Apr 2020).
Phase
Phase 4
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

the effect of ketofol, a combination of propofol and ketamine, on hemodynamics and airway response during induction of general anesthesia has been studied before. Its effect on the smoothness of extubation has not been studied before. In the present study; we aimed to assess the effect of ketofol on the smoothness of extubation as regards, airway response, sedation score during suction and extubation and hemodynamic changes comparing it with propofol for induction of general anesthesia.

Read the detailed description

After securing intravenous access by a 20g catheter, intravenous premedication (midazolam 2 mg and 4mg ondansetron) was administered to all patients. Standard ASA(american society of anesthesiologists) monitoring (5-lead ECG, noninvasive blood pressure (NIBP), and pulse oximetry) was applied to all the patients for the recording of heart rate (HR), NIBP and oxygen saturation by a multiparameter monitor. Induction of general anesthesia was achieved as follows: in Group K (Ketofol group), fifty three female patients received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia while in Group P (Propofol group), fifty three female patients received propofol (2mg/kg) only at the induction of general anesthesia.

Patients in both groups received fentanyl 2 ug\kg and atracurium 0.5 mg\kg. After tracheal intubation, general anesthesia maintained by isoflurane 1.5 volume % in 2 L\min oxygen-air mixture 50:50 and atracurium 0.1 mg\kg every 30 minutes, if needed. At the end of the surgery, inhalational anesthesia was stopped and reversal of the patients was done by injection of neostigmine 0.05mg\ kg and atropine 0.01mg\kg.

Hemodynamics (HR and mean arterial pressure ''MAP'') was assessed at 5 minutes interval from the time of reversal of muscle relaxant up to 30 minutes after extubation.

The level of sedation during suction and extubation was assessed using observer assessment sedation score and the airway response under direct laryngoscopy to suction was noted by five-point scale. After 5 minute interval, the level of sedation and smoothness of extubation was noted by four-point scale.

02

Conditions studied

  • Smooth Extubation

Keywords

  • Ketofol
  • Propofol
  • Laparoscopic Drilling of Polycystic Ovary
03

In context

Polycystic Ovary Syndrome

944 studies on the registry are indexed under Polycystic Ovary Syndrome; 174 are open to participants now.

This study's enrollment of 106 is above the median of 70 across 685 interventional studies indexed under Polycystic Ovary Syndrome.

Browse Polycystic Ovary Syndrome studies →

Lead sponsor

Fayoum University Hospital is the lead sponsor of 73 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • American Society of Anesthesiologists Physical status ''ASA PS'' class I and II scheduled for laparoscopic drilling for polycystic ovary under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • from cardiac, hepatic, renal diseases, history of epilepsy
  • Patient refusal.
  • known drug allergy.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Active comparator
    Group K

    Ketofol group

    Drug: Ketofol as induction agent

  • Active comparator
    Group P

    propofol group

    Drug: Propofol as induction agent

Interventions

  • DrugKetofol as induction agent

    Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia

  • DrugPropofol as induction agent

    Patients who received propofol (2mg/kg) only at the induction of general anesthesia.

06

What researchers measure

Primary outcomes

  1. smoothness of extubation

    Smoothness of extubation Grade Description 1. No coughing on endotracheal tube 2. Coughing on the tube 3. Vomiting 4. Laryngospasm

    Time frame: 5 minutes after extubation

Secondary outcomes

  1. airway response to laryngoscopy and suction

    Grading of air way reflexes Grade Description 1. Excellent(breathing well, no response to laryngoscopy\& suctioning) 2. Good(breathing well, minimal grimacing response to laryngoscope\& suctioning) 3. Satisfactory (breathing well coughing attempt to laryngoscopy\& suctioning) 4. Poor (breathing well, coughing on tube laryngoscopy) 5. Very poor (breathing well, coughing on tube laryngoscopy)

    Time frame: 5 minutes after extubation

  2. sedation score

    Observer assessment sedation score Observation Score Responds readily to name spoken in normal tone 5 Lethargic response to name spoken in normal tone 4 Responds only after name is called loudly and\\or repeatedly 3 Responds only after mild podding or shaking 2 Dose not responds to mild podding or shaking 1

    Time frame: 5 minutes after extubation

  3. Age

    In years

    Time frame: 6 hours before intervention

  4. weight

    In kilograms

    Time frame: 6 hours before intervention

  5. Height

    In meters

    Time frame: 6 hours before intervention

  6. BMI

    In kilogram per square meter

    Time frame: 6 hours before intervention

  7. mean arterial pressure (MAP)

    hemodynamic parameter

    Time frame: 5 minutes before extubation

  8. mean arterial pressure (MAP)

    hemodynamic parameter

    Time frame: 1 minute after extubation

  9. mean arterial pressure (MAP)

    hemodynamic parameter

    Time frame: 5 minutes after extubation

  10. mean arterial pressure (MAP)

    hemodynamic parameter

    Time frame: 10 minutes after extubation

  11. mean arterial pressure (MAP)

    hemodynamic parameter

    Time frame: 15 minutes after extubation

  12. mean arterial pressure (MAP)

    hemodynamic parameter

    Time frame: 20 minutes after extubation

  13. heart rate (HR)

    hemodynamic parameter

    Time frame: 5 minutes before extubation

  14. heart rate (HR)

    hemodynamic parameter

    Time frame: 1 minute after extubation

  15. heart rate (HR)

    hemodynamic parameter

    Time frame: 5 minutes after extubation

  16. heart rate (HR)

    hemodynamic parameter

    Time frame: 10 minutes after extubation

  17. heart rate (HR)

    hemodynamic parameter

    Time frame: 15 minutes after extubation

  18. heart rate (HR)

    hemodynamic parameter

    Time frame: 20 minutes after extubation

07

Study locations

1 site
  • Fayoum University hospital
    Fayoum, Madīnat Al Fayyūm, Faiyum Governorate, Egypt 63514, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04365686
Lead sponsor
Fayoum University Hospital
Responsible party
Atef Mohamed Sayed mahmoud (Lecturer, Fayoum University Hospital) — Principal investigator
First posted
Apr 28, 2020
Start date
Apr 1, 2019
Primary completion
Apr 12, 2020
Completion
Apr 20, 2020
Last update
Apr 28, 2020

Study contacts

Atef S Khalil, MD
principal investigator · Fayoum University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion